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Abstract
To date, few pharmacotherapies have been established for the treatment of alcoholism. There is a plethora of
research concerning the involvement of the opioid-endorphin system in mediating the reinforcing effects of
alcohol. The opioid antagonist naltrexone has been found to be effective in alcohol treatment. In addition, the
mu-opioid antagonist and partial kappa agonist nalmefene was recently approved by the European Medicines
Agency for the treatment of alcoholism. The relevant studies followed a harm-reduction, ‘as needed’ approach
and showed a reduction in alcohol consumption with nalmefene 20mg rather than increased abstinence rates,
(which was not the primary goal of the relevant studies). The available literature is reviewed and discussed.
Nalmefene appears to be a safe and effective treatment for alcohol dependence.
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Introduction
In December 2012, Selincro, containing the opioid antag-
onist nalmefene as the active substance, was approved by
the European Medicines Agency (EMA) for the treatment
of alcoholism. This critical review presents the rationale
for using nalmefene in this indication and the data avail-
able so far. Publications were identified through a
Medline search with the terms ‘nalmefene’ AND ‘alcohol’
(66 hits) or ‘alcohol dependence’ (52 hits). This work is
also an extension of the previous analysis on the use of
opioid antagonists in alcohol dependence, which included
the first three studies on nalmefene (Rosner et al., 2010a).
Background
Apart from nicotine dependence, alcohol use disorders
are still by far the most frequent substance disorders
worldwide (Rehm et al., 2009; Wittchen et al., 2011).
While abuse (harmful use) is characterized by the somatic
or psychiatric problems (and, in DSM only, social prob-
lems) induced by alcohol intake, ICD-10 and DSM-IV
define alcohol dependence by a cluster of somatic, psycho-
logical and behavioural symptoms (Soyka and Kuefner,
2008; Soyka, 2013). The recently published DSM-5 has
abandoned the categorical distinction between abuse
and dependence and follows a dimensional approach:
11 symptoms are given for substance use disorders;
four or more positive symptoms constitute a severe sub-
stance use disorder, two or three a moderate one.
Prevalence estimates for alcohol use disorders range
between 7–10% in European countries and the US
(Grant et al., 2004; Kessler et al., 2005; Rehm et al., 2005;
Pirkola et al., 2006). Global prevalence rates of alcohol
use disorders among adults are estimated to range be-
tween 0–16%, with the highest prevalence rates being
found in Eastern Europe (World Health Organization,
2011). In Europe, 137000 deaths per year are associated
with alcohol consumption, including 39000 cases of
liver cirrhosis, 13000 cases of psychiatric and neurological
disorders, 11000 cases of cardiovascular disorders, 26000
cases of malignant disorders and 18000 suicides (for a re-
view, see Soyka, 2013). The net burden caused by alcohol
consumption in EU countries is 1 in 7 deaths in men and
1 in 13 deaths in women (Rehm et al., 2013) and the econ-
omic burden due to alcoholism is enormous (Laramee
et al., 2013).
Multiple psychosocial and psychotherapeutic ap-
proaches are used to treat alcoholism, including cogni-
tive-behavioural therapies, motivational enhancement,
contingency management, 12-step therapies and family
therapy and case management, among many others
(Miller and Wilbourne, 2002; Berglund et al., 2003;
Prendergast et al., 2006; Soyka et al., 2008; Magill and
Ray, 2009). However, relapse to heavy drinking is very
frequent after conventional alcohol therapies, with
abstinence rates only a little higher than 40% (Soyka,
2013).
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A number of meta-analyses have proven the efficacy of
alcohol treatment in general (Hester and Miller, 1995;
Miller and Wilbourne, 2002), but empirical research sug-
gests that allocation of patients to different treatments ac-
cording to individual patient profiles is very difficult
(Project MATCH Research Group, 1997).
Few pharmacotherapies have been established as
anti-craving drugs to reduce relapse risk or alcohol intake
in alcoholism (Heilig and Egli, 2006; Soyka et al., 2008;
Spanagel and Kiefer, 2008; Soyka and Rosner, 2010).
Empirical evidence is available for the efficacy of the
putative N-methyl-D-aspartic acid (NMDA) modulator
acamprosate and the opioid antagonist naltrexone in
alcohol treatment (Rosner et al., 2010b; Maisel et al.,
2013). Acamprosate is marketed for relapse prevention
of alcoholism and available in many countries world-
wide. Its precise mechanism of action is not fully under-
stood, but many data suggest modulation of the NMDA
receptor as the primary mechanism of action (Littleton
and Zieglgansberger, 2003). Meta-analyses indicate that
acamprosate reduces relapse to heavy drinking or in-
creases the abstinence rates in alcohol-dependent people
(Rosner et al., 2010b; Maisel et al., 2013). Acamprosate
is safe and usually well tolerated. The Cochrane analysis
indicates that only diarrhoea is more frequent in acam-
prosate patients (Rosner et al., 2010b). Some more recent
studies have shown negative results for acamprosate
(Mann et al., 2012). Other drugs are currently being
tested, including baclofen, but none of these agents is
close to being introduced to the market (Davies et al.,
2013; Spanagel and Vengeliene, 2013).
Neurobiological basis
Multiple lines of evidence suggest that opioid receptors
are implicated in the development of alcohol use and
alcoholism (Ciccocioppo et al., 2002). Altered activity of
mu-opioid-receptor–mediated neurotransmission has
been suggested as one of the key mechanisms underlying
the reinforcement of alcohol consumption and develop-
ment of alcoholism (Koob, 1992; Herz, 1997; Cowen and
Lawrence, 1999; Gianoulakis, 2004; Oswald and Wand,
2004).
Three major classes of opioid receptors have been iden-
tified: mu (μ), kappa (κ) and delta (δ) opioid receptors
(Gianoulakis, 2004). Mu and kappa receptors are located
in the grey matter of the spinal cord, limbic system,
hippocampus, thalamus, ventral striatum and the brain-
stem (Kuhar et al., 1973; Hiller et al., 1994; Koob and
Le Moal, 2006). Delta receptors are located throughout
the grey matter of the telencephalon and also the hippo-
campus, mostly in GABAergic neurons (Erbs et al.,
2012). Beta-endorphins are endogenous ligands for the
mu and delta receptors, enkephalins for the delta recep-
tors and dynorphins predominantly for the kappa recep-
tors (Kuhar et al., 1973; Koob and Le Moal, 2006).
Mu receptors play an essential role in mediating the
analgaesic and rewarding effects of opioids and, very
likely, also in physical dependence (Narita et al., 2001).
The μ1 receptor subtype is linked to analgaesia and eu-
phoria, the μ2 subtype to respiratory depression (Boom
et al., 2012).
Alcohol affects many different neurotransmitter
systems in the brain, including glutamate, gamma amino-
butyric acid (GABA), serotonin and especially dopamine
(Koob and Le Moal, 2006; Spanagel, 2009; Spanagel
and Vengeliene, 2013). It stimulates the release of beta-
endorphin, enkephalins and dynorphin (Koob et al.,
2003; Marinelli et al., 2004, 2005, 2006; Dai et al., 2005).
Opioids in the paraventricular nucleus stimulate alcohol
intake (Barson et al., 2010), while blockade of the opioid
receptor has been shown to decrease alcohol intake
(Hubbell et al., 1986, 1988; Herz, 1997; Oswald and
Wand, 2004). There is much evidence suggesting that
the opioid system plays a significant role in mediating
the reinforcing effects of alcohol and the associated dop-
amine release in the mesolimbic brain area (Belluzzi and
Stein, 1977; Goeders et al., 1984; Hubbell et al., 1988;
Reid, 1996; Gianoulakis, 2004; Marinelli et al., 2006;
Jarjour et al., 2009). Opioid receptors in GABAergic
neurons interact with dopaminergic neurons and thus
mediate dopamine release (Koob and Le Moal, 2006)
and midbrain dopamine neurons in the ventral tegmental
area and their projections to the nucleus accumbens in the
ventral striatum are believed to support reward anti-
cipation, reinforcement and motivational processes in
general (Adcock et al., 2006).
The opioidergic system has been viewed as a ‘hedonic’
system. Long-term changes due to substance use may in-
clude receptor densities and effector systems (Turchan
et al., 1999; Chen and Lawrence, 2000) and modifications
of mRNA coding for both receptors and peptides
(Przewlocka et al., 1997; Rosin et al., 1999; Cowen and
Lawrence, 2001).
Functional neuroimaging studies suggest that marked
changes and adaptations in the opioid system are asso-
ciated with chronic alcohol use. Positron emission tom-
ography (PET) studies indicate a negative correlation
between mu-opioid receptor binding and alcohol craving
in recently abstinent alcohol-dependent people (Bencherif
et al., 2004). Heinz et al. (2005) have demonstrated an in-
crease of mu-opioid receptors in different regions of the
brain, including the nucleus accumbens, and a correlation
with the severity of alcohol craving.
Nalmefene – pharmacology, preclinical and clinical
findings and pharmacogenetics
Nalmefene is an antagonist at the mu- and delta-opioid
receptor (DeHaven-Hudkins et al., 1990; Emmerson et al.,
1994) and a partial agonist at the kappa receptor (Bart
et al., 2005a) and has been studied for use in substance
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Nalmefene has a comparable chemical structure to nal-
trexone (Swift, 2013) but was proposed to offer a number
of potential advantages relative to naltrexone (Mason
et al., 1999), including a more effective binding to central
opioid receptors (Emmerson et al., 1994; Ingman et al.,
2005), a higher bioavailability (Gal et al., 1986; Dixon
et al., 1987) and the absence of a dose-dependent associ-
ation with liver toxicity (Mason et al., 1999). There is no
evidence of significant activity at any other receptor
type (for review see Niciu and Arias, 2013). Chronic
nalmefene administration does not change dopamine
receptor function, as shown by animal PET studies
(Unterwald et al., 1997).
Nalmefene is a potent antagonist at the opioid receptor
and is selective for the mu- and kappa-opioid receptor
subtypes (Michel et al., 1985; Bart et al., 2005a). Preclinical
data indicate that kappa-opioid receptor antagonism de-
creases dependence-induced alcohol self-administration
(Walker and Koob, 2008). The relatively higher affinity
of nalmefene at the kappa-receptor may be responsible
for the increased hypothalamic-pituitary-adrenal axis
activation via increased adrenocorticotropic hormone
(Schluger et al., 1998). There is a close interaction between
the opioid system and stress system in alcoholism, and
naltrexone and nalmefene may have different effects on
the systems (Emsley et al., 2013).
In alcohol-dependent rats nalmefene was found to
be significantly more effective in suppressing alcohol
intake than naltrexone (Walker and Koob, 2008). The
results were suggestive of the kappa-opioid receptor com-
petitive antagonism selectively decreasing alcohol self-
administration. Nalmefene-induced elevation in serum
prolactin in healthy volunteers was interpreted as a par-
tial agonist effect at kappa-opioid receptors (Bart et al.,
2005a), while binding assays confirmed nalmefene’s
affinity for kappa-opioid receptors (Bart et al., 2005a).
Data from animal model studies indicate that the in vivo
pharmacology of nalmefene is similar to that of naloxone
and naltrexone (Osborn et al., 2010). Nalmefene has a
slower onset and longer duration of action than
naltrexone.
Pharmacokinetics and pharmacodynamics
Nalmefene has a similar chemical structure to naltrexone
but may somehow bind more tightly to opioid receptors
(Emmerson et al., 1994; Ingman et al., 2005).
In a PET study with the opioid receptor ligand (11c)
carfentanil, Ingman et al. (2005) evaluated the pharmaco-
kinetics of nalmefene (20mg) after single and 7-d re-
peated dosing in 12 healthy volunteers. The regions of
interest were the thalamus, caudate nucleus and frontal
cortex, with the occipital cortex as reference region.
Central mu-opioid receptor occupancy was measured 2,
26, 50 and 74 h after completion of each dosing schedule.
The results indicated that nalmefene was rapidly ab-
sorbed. The mean half-life was 13.4 h after single and
repeated dosing. Nalmefene, thus, has linear pharmaco-
kinetics. Receptor occupancy was high 2 h (87–100%)
and also 26 h (83–100%) after both dosing schedules.
After 50 h receptor occupancy was still 48.4–72.0%,
while the nalmefene plasma concentration was very
low. These results suggest a slow dissociation of the
drug from the mu-opioid receptor.
Previously, Kim et al. (1997) showed a clearance half-
life of 28.7±5.9 h for central opioid receptors and a
plasma elimination half-life of 8.30±0.34 h. Again, the
regions of interest were the thalamus, caudate nucleus,
putamen and cerebral cortex. Nalmefene has an oral bio-
availability of about 40% (Gal et al., 1986; Dixon et al.,
1987; Ingman et al., 2005; European Medicines Agency,
2013). There is no evidence for liver toxicity (Mason
et al., 1999). The opioid kappa receptor system may be
of relevance for motivational aspects of alcoholism and
for mood disorders/depression (Walker and Koob, 2008;
Walker et al., 2011, 2012).
Nalmefene is rapidly absorbed (Dixon et al.,
1987). Tolerance of single doses of 20–300mg daily or
10–40mg twice daily is usually good (Dixon et al., 1987;
Mason et al., 1994). There is no evidence of any serious
adverse drug reactions in hepatic or other body systems.
In the Anton et al. study (2004, see below) the 20mg
group experienced more insomnia, dizziness and con-
fusion, while the 5mg group also showed more dizziness
and the 40mg group more nausea than the placebo
group. Most symptoms were mild and improved over
time. Outcome parameters concerning alcohol intake
did not differ between groups.
Preclinical findings
Nalmefene was found to reduce alcohol consumption
in animal models (June et al., 1998; Ciccocioppo et al.,
2002). Walker and Koob (2008) examined the effects
of naltrexone, nalmefene and nor-binaltorphimine on
alcohol consumption in nondependent and dependent
rats. Nalmefene was found to be significantly more effec-
tive in suppressing ethanol intake than naltrexone in
ethanol-dependent animals. In a human study, nalmefene
was equally effective as naltrexone in reducing subjective
responses to alcohol in non-treatment seeking alcoholics
(Drobes et al., 2004).
The effects of nalmefene on craving and other sub-
jective responses to alcohol-related cues were assessed
in a clinical laboratory study (Drobes et al., 2003, 2004).
Non–treatment-seeking alcoholics and social drinkers
were randomly assigned to receive nalmefene (titrated
to 40mg per day), naltrexone (titrated to 50mg per day)
or placebo for 7 d before they attended an alcohol chal-
lenge clinical laboratory session in which an alcoholic
drink was provided in a bar-like setting. Both nalmefene
and naltrexone reduced craving, drinking amounts and
frequency to a comparable extent among the alcohol-
dependent group, while no effects were observed in the
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social drinker group, relative to placebo. Like naltrexone,
nalmefene reduces the subjective ‘high’ feeling after
alcohol consumption (Drobes et al., 2004).
Clinical findings
To date, six randomized controlled trials have been pub-
lished on the efficacy of nalmefene in alcohol treatment
(Mason et al., 1994, 1999; Anton et al., 2004; Karhuvaara
et al., 2007; Gual et al., 2013; Mann et al., 2013) (see
Table 1). The first was a pilot study with a small sample
size (Mason et al., 1994) in which 21 alcohol-dependent
subjects were randomly assigned to 12 wk of double-
blind treatment with 40mg nalmefene, 10mg nalmefene
or placebo. Patients also attended Alcoholics Anonymous
(AA) support groups and were encouraged to visit other
psychosocial therapies, but no such treatment was pro-
vided in the study. Compared with placebo, nalmefene
significantly decreased the number of drinks per drink-
ing day in both dosing groups (p40.05). An additional,
significant effect on heavy drinking was observed in
the higher (40mg) dosing group, while there was a non-
significant trend of a higher proportion of abstinent days
in the nalmefene groups. This effect was more marked in
the subsequent studies. Nalmefene was well tolerated and
no serious adverse drug reactions occurred.
The same group (Mason et al., 1999) later studied 105
patients who were assigned in a 12-wk study to receive
80mg nalmefene (n=35), 20mg nalmefene (n=35) or
placebo (n=35). Cognitive behavioural therapy was ad-
ditionally provided. Significant effects on rates of heavy
drinking were shown in both nalmefene groups. Heavy
drinking rates were also found to be significantly reduced
when the analysis was limited to the sampler subgroup,
indicating that non-abstinent patients (who had at least
one drink during the trial) also benefit from treatment
to a similar degree. Differences in other outcomes, such
as percentage of abstinent days and the number of drinks
consumed per drinking day were not statistically sig-
nificant. Again, no unexpected serious adverse events
were recorded and rates of adverse events did not differ
between both dosing groups. The authors stated that
the comparatively high patient dropout rate in the
80mg-dosing group indicates that a lower dosing of 20
to 40mg per day may be preferable.
The results of a multicentre trial did not find significant
effects on drinking outcomes for nalmefene (Anton et al.,
2004). The trial evaluated 3 doses of nalmefene (5, 20 and
40mg) in a double-blind comparison with placebo over a
12-wk treatment period. A total of 270 recently detoxified
alcohol-dependent subjects were enrolled. Motivational
enhancement therapy with individualized treatment
goals of total abstinence or drinking reduction was ad-
ditionally provided. Both the nalmefene and placebo
groups showed a reduction in heavy drinking days, crav-
ing and gamma-glutamyl transferase and carbohydrate-
deficient transferrin concentrations over time. The 20mg
group experienced more insomnia, dizziness and
Table 1. Design and outcomes of randomized clinical trials on nalmefene for drinking problems












of drinks or amount of
alcohol per drinking day
Mason et al. (1994) USA 21 0, 10, 40 12 p40.05 (40mg
group only)
p<0.05 p40.05 in both groups





Anton et al. (2004) USA 270 0, 5, 20, 40 12 n.s.
Karhuvaara et al.
(2007)*
Finnland 403 0, 10–40 28 p=0.01 p40.05 p40.01 G-GT also decreased
significantly (p<0.01)





No significant reduction in
alcohol consumption
Mann et al. (2013)* Europe 604 20 vs.
placebo
24 p<0.05 p=0.003
van den Brink et al. (2013)
(Pooled analysis of data
from the Mann et al.
(2013) and Gual et al.
(2013) studies)
Europe 667 20 vs.
placebo




n.s.=not significant (p>0.5); G-GT: gamma-glutamyl transferase.
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confusion, while the 5mg group also showed more dizzi-
ness and the 40mg group more nausea than the placebo
group. Most symptoms were mild. Outcome parameters
concerning alcohol intake did not differ between
groups. Although there were more symptoms of mild-
to-moderate nausea, insomnia and dizziness in the nal-
mefene groups than in the placebo group, the drug was
well tolerated and adverse experiences did not result in
excessive trial termination.
Positive findings were obtained in a Finish multicentre,
randomized, placebo-controlled trial by Karhuvaara et al.
(2007). This study shows significant effects on various
drinking outcomes in a sample of heavy drinkers (N=
403). Concomitant psychosocial intervention was mini-
mal. The risk of heavy drinking decreased significantly
compared to the placebo group, as did the levels of
serum alanine aminotransferase and gamma-glutamyl
transferase. The most common adverse events associated
with nalmefene were nausea, insomnia, fatigue, dizziness
and alcoholic hangover.
The efficacy of nalmefene was studied in two recent
large, adequately powered European randomized con-
trolled trials (Gual et al., 2013; Mann et al., 2013). In con-
trast to the above-mentioned trials, these studies used
an ‘as needed’ approach with nalmefene 18 (20) mg vs.
placebo. They followed a harm reduction approach, i.e.
abstinence was not the primary goal but reduction of
heavy drinking days. No fixed dosing regime was
used. The patients could decide whether to take the
drug or not on a daily basis, depending on whether
they were anticipating alcohol exposure or not. The medi-
cation was taken on about half of the days during
treatment.
Mann et al. (2013) evaluated the long-term safety and
tolerability of as-needed use of 20mg nalmefene vs. pla-
cebo over 52 wk in 579 patients with alcohol dependence
(ClinicalTrials.gov identification number: NCT00811941).
The study showed a significant reduction of daily alcohol
consumption and of heavy drinking days. The number of
patients who discontinued treatment was significantly
higher in the nalmefene group, mostly because of with-
drawal of consent in the placebo group and adverse
events in the nalmefene group. The main treatment-
emerging adverse events leading to dropout were nausea,
dizziness, fatigue and headache and the most frequent
adverse events in general were dizziness, nausea, fatigue
and headache. With respect to secondary parameters,
liver values decreased significantly more in the nalmefene
group than in the placebo group.
Gual et al. (2013) performed a further placebo-
controlled study with a similar design that included
718 patients (358 in the nalmefene group). A total of 218
patients reduced their drinking to 6 heavy drinking
days/month or less or below medium drinking risk level
already in the period between screening and randomiza-
tion. On average, patients took study medication on 65%
of the days in the main treatment period. The co-primary
efficacy analyses showed a significantly superior effect of
nalmefene compared to placebo in the change from base-
line to month six in heavy drinking days. A subgroup
analysis showed that patients who did not reduce
their drinking prior to randomization benefitted more
from nalmefene. In addition, reductions in liver enzymes
were greater in the nalmefene group. In contrast to the
Mann et al. study, the incidence of adverse events leading
to dropout was similar in both groups. Recently, van den
Brink et al. (2013) presented a combined sub-analysis of
data from the Gual et al. (2013) and Mann et al. (2013) stu-
dies. Since some patients had already reduced their al-
cohol drinking before study entry, the authors looked at
patients who did not reduce their consumption after the
initial assessment. The pooled analysis consisted of 667
patients (332 placebo, 335 nalmefene). There was a signifi-
cant effect of nalmefene compared with placebo in reduc-
ing the number of heavy drinking days and total alcohol
consumption as primary endpoints at month six. The
overall efficacy of nalmefene as an ‘as needed’ medication
in this population was larger than in the total study
population.
A further safety study with nalmefene treatment over
11 yr (‘Sense Study’) was presented as a poster only at
the Annual RSA Scientific Meeting, San Francisco,
California, USA, June 23–27, 2012 and confirmed the
good safety profile of nalmefene. In addition, Matz
et al. (2011) did not find relevant ECG changes or QT pro-
longation following treatment with nalmefene.
To summarize, the data the two main studies on
nalmefene as an ‘as needed’ medication for alcohol treat-
ment (Gual et al., 2013; Mann et al., 2013) suggest that
nalemefene does decrease the number of heavy drinking
days and total alcohol consumption. The number of drop-
outs in the Mann et al. (2013) study, but not in the Gual
et al. study (2013), was some 20% higher in the nalmefene
group. Although no novel or unexpected adverse events
were noted, other than the ‘typical’ effects seen in opioid
antagonist treatment, the limited tolerance of the drug
may limit its clinical acceptance. The novel ‘as needed’
approach is of interest and obviously accepted by many
patients as a treatment option. The populations included
seem to be rather moderate drinkers compared to other
study populations (mean alcohol consumption of about
90 g alcohol). As stressed, with reason, by Gual et al.
(2013), there is no clear-cut answer as to what constitutes
a clinically relevant magnitude of heavy drinking. They
mention the European Medicines Agency’s guideline
(European Medicines Agency, 2010) on the development
of medicinal products for the treatment of alcohol de-
pendence, which states that efficacy should also be evalu-
ated in terms of the difference in the percentage of
treatment responders. Since reduction of alcohol drinking
is associated with fewer accidents and less suicide,
aggression and cardiac arrest (Rehm et al., 2010), nalme-
fene or similar drugs may help reduce the risk for these
events.










Over 100 variants of the mu-opioid receptor gene have
been identified (Lotsch and Geisslinger, 2005; Somogyi
et al., 2007). The most common and clinically relevant
single nucleotide polymorphism is A118G, which results
in an amino acid exchange at position 40 from asparagine
to aspartate (Bond et al., 1998). Genetic studies in alcohol-
ism have provided conflicting results concerning the rel-
evance of the functional variant 118G allele in exon 1 of
the OPRM1 gene for the vulnerability risk for alcoholism
(Bart et al., 2005b; Nishizawa et al., 2006; Barr et al., 2007;
Gelernter et al., 2007; Job et al., 2007; van den Wildenberg
et al., 2007; Koller et al., 2012). An association of varia-
tions in the kappa-opioid system with alcohol depen-
dence has also been described (Xuei et al., 2006). The
OPRM1 118G genotype may moderate the subjective
and neuronal response of opioid antagonists on alcohol
and alcohol cue reactivity (Ashenhurst et al., 2012;
Setiawan et al., 2012; Schacht et al., 2013) and modify re-
sponse to treatment with opioid antagonists such as nal-
trexone, although there are conflicting results (Oslin et al.,
2003; McGeary et al., 2006; Gelernter et al., 2007; Anton
et al., 2008, 2012; Kim et al., 2009; Koller et al., 2012;
Oroszi et al., 2009; Kranzler et al., 2013). A recent meta-
analysis supported the role of the A118G polymorphism
of the OPRM1 gene in moderating the effect of naltrexone
in patients with alcohol dependence and treatment re-
sponse (Chamorro et al., 2012).
For nalmefene, a post-hoc analysis of the Karhuvaara
et al. (2007) study (Arias et al., 2008) did not identify
main or moderating effects of the genotypes on drinking
outcomes.
Conclusion
Nalmefene is the first new medication for alcoholism in
over a decade and one of the very few in general that
was been approved for the treatment of this condition.
There is a sound scientific basis and rationale for the
use of opioid antagonists in alcoholism. Nalmefene has
a different receptor profile than the ‘pure’ mu-opioid re-
ceptor antagonist naltrexone. Much fewer preclinical
and clinical data are available for nalmefene (Medline
count for nalmefene/alcohol was 66 hits) than for naltrex-
one (1617 hits). Previous studies have used different
dosages of nalmefene and found that the 20mg tablet is
as effective as higher dosages but has fewer side effects.
The recent meta-analyses on opioid antagonists by
Rosner et al. (2010a), which included the early nalmefene
trials, and Maisel et al. (2013) indicate that opioid antago-
nists reduce alcohol consumption and heavy drinking
days rather than promote abstinence in alcoholism.
Subsequently, the two more recent studies with nalme-
fene followed a harm-reduction approach (Gual et al.,
2013; Mann et al., 2013). Few medications have focused
on a reduction in consumption (for a review, see Aubin
and Daeppen, 2013). For the first time, a so-called
anti-craving drug was tested in this ‘as needed’ setting.
The European Medicines Agency recently approved nal-
mefene for the treatment of alcoholism, but nalmefene
is not yet marketed for use in alcohol dependence in the
USA. Head-to-head comparisons with acamprosate and
naltrexone are not yet available. The side effect profile
of nalmefene corresponds to that typically found in
opioid antagonists (Rosner et al., 2010a), with nausea
probably being the most significant problem. The interest-
ing question will be how to integrate this novel treatment
strategy into conventional alcohol treatment programmes
and how to identify patients who might especially benefit
from this kind of treatment. Although the drug is primar-
ily approved for treatment of alcohol dependence, one
might consider testing nalmefene also in patients with al-
cohol misuse or harmful use to prevent them from slip-
ping into dependence. Other areas might be relapse
prevention after alcohol treatment and treatment of
patients with an excessive ‘binge drinking’ consumption
style. These clinical options remain speculative until nal-
mefene has been tested in these special areas.
Nalmefene appears to be an effective treatment for al-
cohol dependence that clinically may at least have some
safety advantages over naltrexone with respect to hepato-
toxicity. Its partial agonist effect at the kappa receptor is
of scientific interest concerning alcohol intake and de-
pression/dysphoria but must be studied in more detail.
Its effect on relapse to heavy drinking compared to nal-
trexone and other anti-craving compounds has to be stud-
ied in head-to-head comparisons and comparative
meta-analyses.
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